Category: Healthcare>Pharmacy
Subscribe
Jan 15, 2025 | 5 minutes read | All Posts
LLY bridge program: Zepbound patients more willing to pay out-of-pocket
Eli Lilly (LLY) facilitated the rollout of both its blockbuster GLP-1 drugs Mounjaro and Zepbound with bridge programs to drive early sales. But the ...
Learn More
Nov 21, 2024 | 5 minutes read | All Posts
Rinvoq's IBD growth bolstered 3Q24 performance
Rinvoq (ABBV), a mainstay treatment for numerous autoimmune diseases, continues to grow ~50% YoY, long after its initial approval in 2019. Label expa...
Learn More
Nov 14, 2024 | 5 minutes read | All Posts
Mounjaro GLP1 leader in 2024
As supply constraints ease, Mounjaro is emerging as the GLP1 leader. Though our analysis of patient persistence and switches suggest a differentiated...
Learn More
Oct 21, 2024 | 5 minutes read | All Posts
Blueprint poised to elevate Ayvakit to blockbuster status with rapid growth in ISMÂ
Ayvakit quarterly unique patients grew 3x from 2Q23 to 2Q24 according to new research from Earnest pharmacy claims data. Ayvakit, a tyrosine kinase i...
Learn More
Sep 17, 2024 | 5 minutes read | All Posts
Madrigal cultivates Rezdiffra’s foothold in MASH as GLP-1 competitors seek approval
Rezdiffra (MDGL) was approved by the FDA in March 2024, as the first treatment approved for adults with noncirrhotic non-alcoholic steatohepatitis (N...
Learn More
Aug 7, 2024 | 5 minutes read | All Posts
Winrevair: Potential Blockbuster in PAH
Winrevair (MRK) was approved by the FDA on March 26, 2024 and is a breakthrough, first-in-class therapy targeting the underlying cause of pulmonary a...
Learn More
Jul 22, 2024 | 5 minutes read | All Posts
Significant number of ex-Mounjaro patients switch to OzempicÂ
Earnest Analytics partnered with the BMO Capital Markets’ BioPharma team to add insight into GLP1 therapeutic usage....
Learn More
Jul 16, 2024 | 5 minutes read | All Posts
Barriers to GLP1 access drive higher telehealth use by patients living with obesityÂ
Contact Sales for more....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 4: End of Mounjaro’s bridge program drove improved gross-to-net
Contact sales for details....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage
Contact sales for details....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes
Contact sales for details....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes
Contact sales for details....
Learn More
Nov 27, 2023 | 5 minutes read | All Posts
Discontinuations damper Relyvrio’s launch
Early in its launch, Relyvrio made headlines by exceeding the street’s revenue expectations and swiftly bringing Amylyx to profitability. However A...
Learn More
Nov 14, 2023 | 5 minutes read | All Posts
Orladeyo: A Tough Pill to Swallow for Competitors in the HAE SpaceÂ
In December 2020, BCRX's Orladeyo made history as the first FDA-approved oral option to prevent hereditary angioedema (HAE) attacks. Despite being la...
Learn More
Apr 13, 2023 | 5 minutes read | All Posts
Insulet Omnipod 5 Adoption Reaccelerates After Record 2022 Revenue
...
Learn More
Mar 28, 2023 | 5 minutes read | All Posts
Wegovy is Back on Shelves, Picking up Ozempic's Momentum in Obesity
...
Learn More
Aug 4, 2021 | 5 minutes read | Healthcare>Pharmacy
Tepezza Disrupted
More than a year after the landmark FDA approval of Horizon Therapeutics’ Tepezza (teprotumumab) to treat Thyroid Eye Disease (TED), we looked at h...
Learn More
Jul 15, 2021 | 5 minutes read | Healthcare>Pharmacy
Narcolepsy Treatment: Xywav Making Waves
Jazz Pharmaceuticals has historically relied on its top-selling medication Xyrem, a narcolepsy medication, accounting for almost 75% of the companyâ€...
Learn MoreSubscribe
Stay Ahead of the Curve: Join Our Global Community and Get Access to Exclusive Consumer Market Insights, Industry Ranking Reports, Product News, and Market Updates from the Consumer Edge Insight Center